

StageZero Life Sciences Ltd.

Nine-month periods ended September 30, 2024 and 2023

Unaudited, condensed consolidated interim financial statements and associated notes

[Expressed in US dollars, unless otherwise noted]

StageZero Life Sciences Ltd.

Unaudited Condensed Consolidated Interim Financial Statements **Nine-month periods ended September 30, 2024 and 2023** **[Expressed in US dollars, unless otherwise noted]**

Consolidated Financial Statements

Consolidated Statements of Financial Position	3
Consolidated Statements of Loss and Comprehensive Loss	4
Consolidated Statements of Changes in Shareholders' Equity (Deficiency)	5
Consolidated Statements of Cash Flows	6
Notes to the Consolidated Financial Statements	7- 18

STAGEZERO LIFE SCIENCES LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
[EXPRESSED IN US DOLLARS]

	<i>Notes</i>	September 30, 2024	December 31, 2023
		\$	\$
ASSETS			
Current			
Cash		15,032	26,353
Trade and other receivables		92,679	88,594
Inventories	4	52,169	22,570
Short-term portion of prepaid expenses and deposits		75,154	90,016
Total current assets		235,034	227,533
Non-current assets			
Property, plant and equipment, net		167,648	214,008
Right of use assets		178,065	202,101
Total non-current assets		345,713	416,109
Total assets		580,747	643,642
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)			
Current			
Trade and other payables	5	9,089,992	7,851,681
Deferred revenues	15	37,685	68,631
Short-term portion of lease liabilities		45,266	39,869
Fair value of convertible debenture	6[c]	54,950	54,950
Short-term loan	6[d]	367,239	428,925
Short-term liabilities		67,340	67,340
Short-term portion of warrant liability	7	-	181
Short-term portion of notes payable	6[a][b]	663,886	437,764
Total current liabilities		10,326,358	8,949,341
Non-current liabilities			
Long-term portion of warrant liability	7	377,994	426,310
Long-term portion of lease liabilities		128,847	163,462
Long-term loan		44,544	44,544
Long-term portion of notes payable	6[b]	828,936	727,610
Total non-current liabilities		1,380,321	1,361,926

STAGEZERO LIFE SCIENCES LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
[EXPRESSED IN US DOLLARS]

Total liabilities		11,706,679	10,311,267
Shareholders' equity (deficiency)			
Share capital	8[b]	101,906,557	101,906,557
Contributed surplus	8[d]	13,260,769	13,225,151
Accumulated other comprehensive income		1,234,743	1,248,663
Deficit		(127,528,001)	(126,047,996)
Total shareholders' deficiency		(11,125,932)	(9,667,625)
Total liabilities and shareholders' deficiency		580,747	643,642
Commitments and contingencies	17		
Subsequent event	18		

See accompanying notes to the consolidated financial statements.

Approved by the Company's board of directors and authorized for issue on December 13, 2024:

(signed) James R. Howard-Tripp, Director

(signed) Garth MacRae, Director

STAGEZERO LIFE SCIENCES LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
[EXPRESSED IN US DOLLARS]

		Three-month period ended September 30		Nine-month period ended September 30	
		2024	2023	2024	2023
	<i>Notes</i>	\$	\$	\$	\$
REVENUES	<i>19</i>	499,663	745,488	1,411,667	2,205,769
Cost of revenue	<i>11</i>	569,262	577,075	1,247,051	1,779,713
Gross profit		(69,599)	168,413	164,616	426,056
EXPENSES					
Research and development	<i>11</i>	-	19,728	-	163,972
Sales and marketing	<i>11</i>	-	(12,660)	-	80,119
General and administrative	<i>11</i>	282,523	922,079	1,507,626	3,018,654
Total Expenses		282,523	929,147	1,507,626	3,262,745
Loss from operations		(352,122)	(760,734)	(1,343,010)	(2,836,689)
			34,294		(81,526)
Loss (gain) from fair valuation of warrants	<i>9</i>	-	-	(48,497)	-
Change in fair value of convertible debenture	<i>8[c]</i>	-	-	-	13,583
Finance and transaction costs	<i>17</i>	47,155	26,854	140,573	266,575
		47,155	61,148	92,076	198,632
Net loss before income taxes		(399,277)	(821,882)	(1,435,086)	(3,035,321)
Current income taxes		-	-	-	-
Deferred income taxes		-	-	-	-
Net loss after income taxes		(399,277)	(821,882)	(1,435,086)	(3,035,321)
Other comprehensive (loss) income: foreign translation adjustment		-	-	-	-
Total loss and comprehensive loss for the year		(399,277)	(821,882)	(1,435,086)	(3,035,321)

STAGEZERO LIFE SCIENCES LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
[EXPRESSED IN US DOLLARS]

Basic and diluted loss per common share	<i>10</i>	(0.00)	(0.01)	(0.01)	(0.03)
--	-----------	---------------	--------	---------------	--------

See accompanying notes to the consolidated financial statements.

STAGEZERO LIFE SCIENCES LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN
SHAREHOLDERS' EQUITY (DEFICIENCY)
[EXPRESSED IN US DOLLARS]

	Share capital		Contributed surplus	Accumulated other comprehensive income
	Shares	Amount		
	#	\$	\$	\$
	<i>[note 10[b]]</i>		<i>[note 10]</i>	
Balance at January 1, 2024	123,532,948	101,906,557	13,225,151	1,248,663
Net loss for the year	-	-	-	-
Share-based compensation	-	-	35,619	-
Issuance of common shares in convertible debenture conversion				(13,920)
Balance at June 30, 2024	123,532,948	101,906,557	13,260,770	1,234,743
	Share capital		Contributed surplus	Accumulated other comprehensive income
	Shares	Amount		
	#	\$	\$	\$
	<i>[note 10[b]]</i>		<i>[note 10]</i>	
Balance at January 1, 2023	105,464,611	101,392,225	12,909,025	1,234,743
Net loss for the year	-	-	-	-
Share-based compensation	-	-	316,126	-
Issuance of common shares in capital commitment	4,711,226	159,801		
Issuance of option exercise	1,469,409	50,062		
Issuance of warrant exercise	215,354	10,593		
Issuance of common shares in convertible debenture conversion	11,672,348	293,876	-	13,920
Balance at December 31, 2023	123,532,948	101,906,557	13,225,151	1,248,663

See accompanying notes to the consolidated financial statements.

STAGEZERO LIFE SCIENCES LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
[EXPRESSED IN US DOLLARS]

		Three-month period ended		Nine-month period ended	
		September 30, 2024	September 30, 2023	September 30, 2024	September 30, 2023
<i>Notes</i>					
OPERATING ACTIVITIES					
Net profit (loss) for the period		(399,277)	(821,882)	(1,435,086)	(3,035,321)
Non-cash adjustments					
Share-based compensation	8[d]	11,893	261,092	35,619	391,418
Depreciation	9	(16,728)	38,098	45,360	157,250
Change in right of use property		-	68,032	-	148,003
Change in fair value of convertible debenture		-	9,078	-	13,583
Non-cash interest expense		20,613	672	101,326	260,090
Non-cash change in interest on lease liability		5,839	1,639	18,544	11,890
Foreign exchange		73,106	9,260	(93,423)	7,266
(Gain)/loss on revaluation of warrants		-	(197,346)	48,497	(81,526)
		(304,554)	(631,357)	(1,279,163)	(2,127,347)
Changes in non-cash working capital balances related to operations					
Trade and other receivables		46,140	(6,240)	(4,085)	(51,011)
Contract Liability		477	114,713	(30,946)	62,635
Prepaid expenses and deposits		(31,847)	59,902	14,862	(41,967)
Inventory		(29,599)	60,373	(29,599)	73,051
Trade and other payables		329,640	450,425	1,183,361	1,930,637
Cash used in operating activities		10,257	47,816	(145,570)	(154,002)
FINANCING ACTIVITIES					
Short-term loan proceeds		-	-	36,775	254,318
Payment of principal to Health Diagnostic Laboratories Inc.	6[a]	-	(47,000)	-	(47,000)
Repayment of lease liability		(15,946)	(69,671)	(47,840)	(205,646)
Repayment of short-term loan		-	-	-	(227,621)
Proceeds from issuance of units		-	18,519	-	18,519
Proceeds from note payable		-	-	210,000	50,000

STAGEZERO LIFE SCIENCES LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
[EXPRESSED IN US DOLLARS]

Proceeds from stock option exercise	-	-	-	37,037
Proceeds from issuance of shares and warrants for capital commitment	-	-	-	279,764
Proceeds from warrant exercise	-	10,222	-	10,222
Payment of note payable and interest	-	-	(64,686)	(7,183)
Cash provided by financing activities	(15,946)	(87,930)	134,249	162,410
INVESTING ACTIVITIES				
Net decrease in cash during the period	(5,689)	(40,114)	(11,321)	8,408
Cash, beginning of period	20,721	64,206	26,353	15,684
Cash, end of period	15,032	24,092	15,032	24,092

See accompanying notes to the consolidated financial statements.

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

1. NATURE OF OPERATIONS AND GOING CONCERN

StageZero Life Sciences, Limited (“StageZero Life Sciences”, the “Company”, “we”, “us”, “our”) is a vertically integrated healthcare company at the nexus of three of the fastest growing and most exciting sectors of healthcare today; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. The Company is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention.

In its laboratory business the company continues to develop and commercialize proprietary molecular diagnostic tests for early detection of diseases and personalized health management, with a primary focus on cancer-related indications. The Company has developed a proprietary platform technology, the Sentinel Principle®, to identify novel biomarkers from whole blood. The Company’s lead product, Aristotle®, is a blood-based molecular diagnostic assessment that can detect an individual’s current risk for potentially having a variety of cancers.

The Company acquired the CareOncology businesses of Health Clinics Ltd, and Health Clinics USA Corp (“CareOncology”) in the third quarter of 2021 (Note 3). CareOncology operates virtual clinics as well as a physical clinic in the UK, that operate on a global telehealth platform and provide clinical consultations, interventions and monitoring services for patients diagnosed with cancer through the CareOncology Protocol (TREAT Program). CareOncology has also developed the AVRT program, which evaluates a patient’s potential risk of developing cancer and a variety of other chronic illnesses. AVRT provides monitoring/interventions that are intended to target the inflammatory and metabolic pathways that underlie the progression of many diseases.

In 2023 and the first three quarters of 2024, the Company focused on its CareOncology businesses and also the development and commercialization of Aristotle.

The Company is incorporated under the laws of the Province of Ontario and is domiciled in Ontario, Canada. Its shares are publicly traded under the stock symbol SZLS on the Toronto Stock Exchange. The Company’s registered office is located at Unit 30, 70 East Beaver Creek Road, Richmond Hill, Ontario, L4B 3B2.

StageZero Life Sciences Ltd. has wholly owned subsidiary companies, StageZero Holdings Inc., which owns 100% of StageZero Life Sciences Inc. (“Inc.”), CareOncology, Inc, and SZ Physician Holdings, Inc, all in the United States, and Clinics Operations, Ltd. (also referred to as CareOncology UK).

These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the future operations will allow for the realization of assets and the discharge of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments to the carrying value and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern, and such adjustments could be material. The Company reported a consolidated net loss of \$0.4 million for the three months ended September 30, 2024 [September 2023 – loss of 0.8 million]. A loss of \$1.4 million for the nine-month period ended September 30, 2024 [2023 – loss of \$3.0 million]. As at September 30, 2024, the Company had working capital deficit of \$10.1 million [December 31, 2023, working capital deficit of \$8.7 million] and a deficit of \$128 million [December 31, 2023 – \$126 million].

These circumstances create material uncertainties that cast significant doubt as to the ability of the Company to continue as a going concern and, hence, as to the appropriateness of the use of accounting principles applicable to a going concern. The Company is actively pursuing additional financing to further develop certain of the Company’s commercial and scientific initiatives; but there is no assurance these initiatives will be successful, timely or sufficient.

2. BASIS OF PRESENTATION

These consolidated financial statements have been prepared on a historical cost basis, except for the revaluation of certain financial instruments. The Company’s principal accounting policies outlined below have been applied consistently to all periods presented in these condensed consolidated interim financial statements.

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

Statement of compliance

These condensed consolidated interim financial statements have been prepared using accounting policies consistent with International Financial Reporting Standards (“IFRS”), and in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (“IASB”). These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2022 and the unaudited consolidated financial statements for the year ended December 31, 2023, which have been prepared in accordance with IFRS as issued by the IASB. The accounting policies followed in these condensed consolidated interim financial statements are consistent with those applied in the Company’s consolidated financial statements for the year ended December 31, 2022 and 2023. These condensed consolidated interim financial statements were approved and authorized for publication by the Board of Directors on December 13, 2024.

Accounting standards, amendments, and interpretations not yet adopted or effective

As discussed in the notes to the Company’s audited financial statements for the year ended December 31, 2023 certain new standards, amendments, and interpretations have been issued which are not yet effective for the Company’s consolidated financial statements for the periods presented. The Company has not early adopted any standards, amendments, or interpretations, which are issued but not yet effective.

3. ACQUISITION OF CAREONCOLOGY BUSINESS

On September 2, 2021, the Company acquired 100% of the shares of Clinics Operations Limited (“COL”), a company incorporated in England and, through the Company’s newly incorporated subsidiaries, CareOncology Inc. (“COI”) and CareOncology Physicians (“COP”), the operating assets of Health Clinics USA Corp. Both were acquired from Health Clinics Limited (“HCL”), the ultimate parent of both entities, for consideration with a fair value of \$7,283,827.

The consideration was comprised of: 12,500,000 shares issued on the date of closing, September 2, 2021; 2,500,000 shares that were issued upon the successful acquisition of a Care Quality Commission (“CQC”) license by COL (the “CQC Consideration”), October 22, 2021; and contingent consideration consisting of 8,000,000 common shares, pending approval by the Company’s shareholders. The 12,500,000 shares were valued based on the share price at issuance, September 2, 2021, being Cdn\$ 0.42, or \$4,160,625. These shares were subject to a Lock Up Agreement that restricted the Holders’ ability to sell those shares, releasing one third four months from the closing date, one third eight months from the closing date, and the final third on the anniversary of the closing date. On December 10, 2021 the shareholders elected to award the issuance of the 8,000,000 common shares upon achieving the Earn Out Consideration. Since the Earn Out Consideration revenue target was not attained in a continuous 12-month period between September 2021 and December 31, 2022, the 8,000,000 shares were not earned and are no longer due..

Company issued the additional 2,500,000 common shares on December 2, 2021, upon Clinic Operations Limited obtaining a Care Quality Commission license in England and accordingly, the related shares were valued using the same closing price, at \$832,125.

4. INVENTORIES

Inventories comprise lab supplies and test kits.

	At September 30, 2024	At December 31, 2023
Inventory	52,169	22,570
Impairment of inventory	-	-
Total Inventory	52,169	22,570

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

5. TRADE AND OTHER PAYABLES

The Company's exposure to liquidity and currency risks related to trade and other payables is presented in note 12.

	At September 30, 2024	At December 31, 2023
	\$	\$
Trade payables	3,984,917	3,811,586
Accrued directors' compensation	620,000	540,000
Accrued salary related expenses	3,645,555	2,783,255
Other accrued liabilities	839,520	716,840
Total trade payables and accrued liabilities	9,089,992	7,851,681

6. NOTES PAYABLE AND CONVERTIBLE DEBENTURES

Notes payable consists of:

	At September 30, 2024	At December 31, 2023
	\$	\$
Note payable to HDL [a]	948,936.00	847,610.00
Note payable to shareholders and a director [b]	543,889.00	317,764.00
Total	1,492,825.00	1,165,374.00
Less: current portion of notes payable	(663,886.00)	(437,764.00)
Long-term portion of notes payable	828,939.00	727,610.00

Convertible debenture held at fair value consists of:

	At September 30, 2024	At December 31, 2023
	\$	\$
Convertible debenture [c]	-	54,950

Term loans consist of:

At September 30, 2024 **At December 31, 2023**

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

	\$	\$
Other loans [d] (short-term)	367,239	428,925
CEBA Loan [d] (long-term)	44,544	44,544

[a] Note payable to HDL

In May 2015, StageZero Holdings issued a note payable in the amount of \$1.0 million to Health Diagnostic Laboratories (HDL) to purchase additional shares of StageZero Life Sciences Inc. (formerly Innovative Diagnostic Lab) increasing its share from 33⅓% to 50% and in March 2016, StageZero Holdings assumed an additional \$1.0 million note payable to HDL to own 100% of StageZero Life Sciences Inc. Effective March 1, 2017, the Company agreed to pay principal of \$2,095,843.

On March 1, 2017 the Company and HDL's representative reached an agreement pursuant to which StageZero Holdings would pay the principal amount of \$2,095,843, to be paid in a \$25,000 upfront payment and monthly payments of \$15,000 beginning March 1, 2017 to July 1, 2017, followed by monthly payments of \$10,000 until the outstanding debt has been paid in full.

The note payable was initially recognized at fair value, and subsequently measured at amortized cost using the effective interest rate method. The initial fair values were calculated with a valuation technique that uses parameters obtained from observable markets, including credit spread and interest rate volatility. The prevailing interest rate used in the valuations was 16% at initial recognition. The loan is unsecured, and the balance of the note is expected to be repaid in full by 2034. During nine months ended September 30, 2024, the Company paid nil [2023 - nil]

[b] Notes payable to shareholders and director

At September 30, 2024, the convertible notes payable balance is \$543,886 including accrued interest payable, which approximates the fair value. The notes are secured by a security interest in the Company's patents and trademarks.

[c] Convertible debenture

Convertible Debenture Private Placement in August 2022

The Company closed a private placement of convertible debentures for gross proceeds of Cdn\$177,000 in August, 2022 (the "Offering"). Each Unit is composed of (i) a \$1,000 unsecured convertible debenture, bearing interest at a rate of 8% per annum, having a term of eighteen (18) months from the date of issuance and is convertible into common shares of the Company, at a conversion price of \$0.11 per Common Share, and (ii) 9090 Common Share purchase warrants. Each Warrant is exercisable into one (1) Common Share of the Company at an exercise price of CAD\$0.15 per Common Share for a period of eighteen (18) months from the date of issuance of the Units. Securities issued pursuant to the Offering are subject to a statutory hold period lasting four (4) months and a day after the issuance of the securities.

	Fair value of convertible debenture
	\$
At January 1, 2024	54,950
Issuance during the period	-
Revaluation during the period	-
Less: Conversion	54,950

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

At September 30, 2024

-

[d] Short-term and long-term loans

During 2020 and second quarter of 2021, the Company received a Cdn\$60,000 Canada Emergency business Account (“CEBA”) loan from the Government of Canada via its commercial bank. The loan was interest free until January 18, 2024, with a maturity date of December 31, 2025. If Cdn\$40,000 of the loan had been repaid by January 18, 2024, the remaining balance (maximum Cdn\$20,000) would have been forgiven. Since the loan was not repaid by January 18, 2024, interest at 5% will be charged per annum until maturity on December 31, 2025. The loan is unsecured.

In 2023, the Company received a loan in the amount of \$367,239 (2022 - \$45,716) from a third party. The outstanding balance as at September 30, 2024 is \$35,534. The loan from the third party is secured by a security interest in the Company’s accounts receivable.

7. WARRANT LIABILITY

	#	\$
At January 1, 2023	48,356,982	794,360
Warrant issued on April 13, 2023	4,419,922	126,111
Warrant issued on April 21, 2023	291,304	8,332
Warrant issued May 9, 2023	270,143	7,770
Warrant issued on June 16, 2023	897,797	26,121
Warrant issued on July 12, 2023	612,951	18,003
Warrant issued on July 28, 2023	423,942	12,595
Warrant Exercised on July 13, 2023	(215,354)	-
Warrant expired during the year	(14,622,744)	-
Fair value changes	-	(566,801)
At December 31, 2023	40,434,943	426,491
Warrant expired during the year	(7,862,554)	-
Fair value changes	-	(48,497)
At September 30, 2024	32,572,389	377,994

No warrants were issued during the nine-month period in 2024 and above warrants are Long-term warrant liability.

The weighted average exercise price for total outstanding warrants as at September 30 2024 is Cdn\$ 0.30.
The exchange rate of USD to Cdn\$ was 1.3499 at September 30, 2024.

Financial liability accounting

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

Because such warrants were denominated in Cdn\$ [a currency different from the Company's functional currency], they were recognized as a financial liability at fair value through profit or loss, except for broker warrants issued to Hampton Security Company, National Bank Financial Inc., Fidelity Clearing Canada ULC, and H.C. Wainwright & Co., LLC. which were compensation warrants and were recorded as contributed surplus in accordance with IFRS 2, Share-based Payments. The fair value of each warrant is estimated on the date of grant and on the valuation date using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires four subjective assumptions, including future stock price volatility of the Company's common shares which trade on the TSX ("Expected volatility"), the risk-free interest rate (sourced to Government of Canada Bond Yields for the noted term); expected dividend yield and expected time until exercise ("Expected life"), which greatly affect the calculated values.

The fair values of the warrants, except for broker warrants issued to Hampton Security Company, National Bank Financial Inc., Fidelity Clearing Canada ULC and H.C. Wainwright, was computed at June 30, 2024 using the Black-Scholes option pricing model with the following assumptions (all with dividend yield of nil):

	Expiry date (mm/dd/yy)	Expected volatility	Risk-free interest rate	Expected life	Weighted- average fair value at measurement date (in Cdn\$)
Date issued:					
26-Nov-21	11/26/2025	141%	3.39%	1 years and 2 months	0.00496
2-Mar-22	3/2/2026	141%	3.39%	1 years and 5 months	0.01287
22-Nov-22	11/22/2027	141%	3.39%	2 years and 2 months	0.02707
13-Apr-23	4/13/2028	141%	3.39%	3 years and 7.5 months	0.02867
21-Apr-23	4/21/2028	141%	3.39%	3 years and 7.5 months	0.02875
9-May-23	5/9/2028	141%	3.39%	3 years and 7 months	0.02894
16-Jun-23	6/16/2028	141%	3.39%	3 years and 4.5 months	0.02932
12-Jul-23	7/12/2028	141%	3.39%	3 years and 9.5 months	0.02957
28-Jul-23	7/28/2028	141%	3.39%	3 years and 10 months	0.02972

The exchange rate of USD to Cdn\$ was Cdn\$ 1.3499 at September 30, 2024.

8. SHARE CAPITAL

[a] Authorized

An unlimited number of non-voting preference shares, issuable in one or more series. Issued: none (2023: none). An unlimited number of voting special shares, entitling the holder to a dividend if and when declared by the Board in parity with the common shares and convertible into common shares. Issued: none (2023: none).

An unlimited number of voting common shares. Issued: 123,532,948 common shares.

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

[b] Financings

Capital commitment agreement

On November 21, 2022, the Company announced that it had entered into a capital commitment agreement with GEM Global Yield Fund LLC SCS (“GEM”) for a Cdn\$25 million Capital Commitment. Proceeds raised from the investment will be used for working capital and general corporate purposes, but especially to expand collaborations with employers, clinic and healthcare systems, and the insurers who support them. In December 2022, the Company issued 4,731,328 common shares and 4,731,328 warrants and received \$206,004 (Cdn\$280,000) under the agreement.

The commitment by GEM will provide funding up to CDN\$25 million. The fee charged by GEM for the \$25 million commitment is 2% or \$500,000, which can be paid to them over the period that the funding is drawn down.

In 2023, the Company issued 4,711,226 common shares and 6,916,059 warrants and received \$360,550 (Cdn\$483,137) under the agreement.

[c] Weighted-average number of shares

On September 18, 2020 the Company announced that trading of the common shares on the TSX on a post-Consolidation basis commenced at market opening on September 18, 2020. The Company’s options, warrants, including its TSX-listed warrants, and convertible debentures have also proportionately been adjusted in accordance with their terms effective September 18, 2020. All shares and purchase amounts in these consolidated financial statements have been retroactively restated to reflect the 1 for 8 consolidation. The weighted-average number of shares outstanding (post-consolidation) for period ended September 30, 2024, is 123,532,948 [December 31, 2023 – 123,532,948].

The Company has not adjusted its weighted-average number of shares outstanding for the purpose of calculating the diluted loss per share, as any adjustment would be antidilutive. All issued and outstanding stock options at September 30, 2024 of 14,514,219 [December 31, 2023 –14,514,219] and warrants of 32,572,389 (post-consolidation) [December 31, 2023 – 40,434,943] are deemed anti-dilutive such that the basic and net loss per share are equal.

[d] Employee stock option plan

On May 25, 2000, the Company adopted a stock option plan (the “Plan”) pursuant to which the Board may grant stock options to directors, officers, employees or consultants of the Company. The current terms of the Plan, approved by the Company’s shareholders on June 30, 2016, provide that the maximum number of common shares available for issuance under the Plan does not exceed 15% of the Company’s issued and outstanding shares at any time. All options granted have a term of five years from the date of grant. The vesting schedule of all granted options is determined at the discretion of the Board. The exercise price of an option must be not less than the closing price of the Company’s common shares on the TSX on the trading day immediately preceding the date the option is granted. As at September 30, 2024, there were 14,514,219 [December 31, 2023 –14,514,219] options outstanding, representing 12% [2023 – 12%] of the Company’s issued and outstanding common shares. All exercised options are settled by the issuance of the Company’s common shares.

There were no option cancellations or modifications to the Plan during the nine-month periods ended September 30, 2024 and 2023.

In compliance with current accounting standards, the fair value of each stock option is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes model requires four subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values. The following assumptions were used to calculate the weighted-average fair values of the stock options granted during the years ended:

	September 30, 2024	September 30, 2023
Expected option life in years	4.1	4.2

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

Expected volatility	149%	167%
Risk-free interest rate	3.34%	3.53%
Vesting period in years	0.5	0.5

The following table summarizes the measurement date weighted-average fair value of stock options granted during the periods ended September 30, 2024 and 2023:

	Number of options granted	Grant date weighted-average fair value
	#	(In Cdn\$)
Nine months ended September 30, 2024	-	-
Nine months ended September 30, 2023	6,717,000	0.065

The following is a summary of the status of the Plan at September 30, 2024 and 2023, and changes during the periods then ended:

	Nine-month period ended September 30,			
	2024		2023	
	Number of options	Weighted-average exercise price	Number of options	Weighted-average exercise price
	#	Cdn\$	#	Cdn\$
Outstanding, beginning of period	14,514,219	0.315	6,865,524	0.456
Granted	-	-	9,093,551	0.065
Exercised	-	-	(1,469,409)	0.065
Expired or forfeited	-	-	(672,500)	0.638
Outstanding, end of period	14,514,219	0.315	13,817,166	0.227
Exercisable, end of period	14,514,219	0.315	12,717,166	0.241

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

The following table summarizes information about stock options outstanding at September 30, 2024:

Year issued	Year of expiry	Range of exercise prices per share	Number outstanding	Number exercisable	Weighted-average exercise price	Weighted-average remaining contractual life
		Cdn\$	#	#	Cdn\$	years
2023	2028	\$0.07	8,221,195	8,221,195	\$0.07	4.00
2022	2027	\$0.15	2,740,000	2,740,000	\$0.15	3.72
2020	2025	\$0.44	1,681,250	1,681,250	\$0.44	1.52
2019	2024	\$0.80	1,862,399	1,862,399	\$0.80	0.56
2017	2027	\$1.52	9,375	9,375	\$1.52	3.41
			14,514,219	14,514,219		

9. EXPENSES BY NATURE

Expenses included in the consolidated statements of loss for nine-month period ended September 30, 2024 and 2023, are as follows:

	For nine months period ended September 30,					
	2024			2023		
	Direct costs	General and administrative	Total	Direct costs	General and administrative	Total
	\$	\$	\$	\$	\$	\$
Salaries and benefit	1,197,961	748,052	1,946,013	1,409,307	1,031,306	2,364,853
Share-based compensation	-	35,619	35,619	-	391,418	391,418
Rent and facilities	25,786	22,054	47,840	110,846	94,800	205,646
Depreciation	-	45,360	45,360	148,730	157,250	305,980
Professional fee	-	428,738	428,738	-	527,328	527,328
Public entity costs	-	21,740	21,740	-	228,274	228,274
Lab supplies and equipment maintenance	23,304	-	23,304	59,679	-	59,679
Officer equipment and maintenance	-	97,604	97,604	-	228,045	228,045

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

Shipping and courier	-	5,179	5,179		31,965	31,965
Other	-	194,939	194,939	51,421	371,537	509,612
Foreign exchange (gain)	-	(91,659)	(91,659)	-	(43,269)	(43,269)
	1,247,051	1,507,626	2,754,677	1,779,713	3,018,654	4,722,877

10. RELATED-PARTY TRANSACTIONS

The key management personnel of the Company at September 30, 2024 and 2023 are the directors, including the Chairman and Chief Executive Officer and the Interim CFO and Corporate Secretary.

Compensation for key management personnel of the Company is detailed below for nine months ended September 30, 2024 and 2023:

	Three Months Ended September 30		Nine Months Ended September 30	
	2024	2023	2024	2023
	\$	\$	\$	\$
Salaries, fees and short-term benefits	97,500	97,500	292,500	292,500
Share-based compensation	-	-	-	200,295
	97,500	97,500	195,000	492,795

As at September 30, 2024, key management personnel controlled 11% (2023-2.0%) of the issued and outstanding common shares of the Company and \$1,174,373 (2023-\$793,958) of compensation remains unpaid to current and former key management personnel which is included in trade and other payables. Such amounts are unsecured, non-interest bearing with no fixed terms of repayment.

Stock options held by key management personnel to purchase common shares have the following expiry dates and exercise prices:

Year issued	Year of expiry	Range of exercise prices per share	Number outstanding	
			At September 30, 2024	At December 31, 2023
		\$	#	#
2019	2024	0.8	1,371,357	1,371,357
2020	2025	0.44	1,187,500	1,187,500

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

2022	2027	0.15	2,740,000	2,740,000
2023	2028	0.065	4,467,000	-
			9,765,857	5,298,857

11. SEGMENT INFORMATION

During the nine month period in 2024,, management has focused on its operations respecting cancer testing and care. Consequently, the Company has one reportable operating segment, operating in two major geographic areas, North America and Western Europe.

12. FINANCIAL INSTRUMENTS AND FINANCIAL RISK-MANAGEMENT OBJECTIVES AND POLICIES

The Company is exposed to liquidity, credit and market risk, the management of which is overseen by the Company's senior management.

The reader is cautioned that audited financial statements for the year ended December 31, 2023 have not been completed. Accordingly, changes to the opening balance sheet as at January 1, 2024 may necessitate changes to the financial statements for the nine-months period ended September 30, 2024.

[a] Financial instruments

The fair value of warrants is estimated using the Black-Scholes option pricing model incorporating various inputs including the underlying price volatility and discount rate, [see *note 7*]. All other notes payable were initially recognized at fair value, and subsequently were measured at amortized cost using the effective interest rate method, whereby the fair value of the notes payable approximates their carrying value. As at September 30, 2024, the Company's warrant liability and notes payable, are carried on the consolidated statements of financial position at fair value, warrant liability has been classified as Level 2, and notes payable have been classified as Level 3, in the fair value hierarchy.

[b] Liquidity risk

Liquidity risk represents the contingency that the Company is unable to gather the funds required with respect to its financial obligations at the appropriate time and under reasonable conditions. The Company attempts to manage this risk in order to ensure that it has sufficient liquidity to be able to honour its current and future financial obligations under normal conditions and in exceptional circumstances. Financing strategies to ensure the management of this risk include resorting to the capital markets through the issuance of equity or debt securities.

The Company's ability to continue as a going concern depends upon its ability to achieve profitable operations and raise additional capital. In the past three years, the Company has earned limited revenue. During 2024 and 2023, the Company completed a series of common share, structured notes payable, capital commitment, common share and warrant and convertible debenture financings. The Company expects to continue to pursue further financings as or until operations become profitable.

The tables below summarize the maturity profile of the Company's financial instruments as at September 30, 2024 and December 31, 2023:

	1 year or less	1 to 5 years	5 years or more	Total
At September 30, 2024	\$	\$	\$	\$
Financial assets				
Cash	15,032	-	-	15,032

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

Trade and other receivables	92,679	-	-	92,679
Financial liabilities				
Trade and other payables	9,089,992	-	-	9,089,992
Notes payable	657,763	480,000	735,844	1,873,607
Short-term loans	367,239	-	-	367,239
Long-term loans	-	44,544	-	44,544
Short-term liabilities	67,340	-	-	67,340
	1 year or less	1 to 5 years	5 years or more	Total
At December 31, 2023	\$	\$	\$	\$
Financial assets				
Cash	26,353	-	-	26,353
Trade and other receivables	88,625	-	-	88,625
Financial liabilities				
Trade and other payables	7,851,508	-	-	7,851,508
Notes payable	437,764	480,000	735,844	1,653,608
Short-term loans	428,925	-	-	428,925
Long-term loans	-	44,544	-	44,544
Short-term liabilities	67,340	-	-	67,340

[c] Credit risk

The Company's financial assets that are exposed to credit risk consist primarily of cash and other receivables.

[d] Market risk

Market risk is comprised of foreign exchange rate risk and interest rate risk.

Foreign exchange rate risk

The Company operates in Canada, the United States, and United Kingdom, and transacts business primarily with US partners and suppliers. During the nine-month period ended September 30, 2024, a 5% appreciation (depreciation) in the Cdn\$ to US dollar foreign exchange rate, with all else being equal, would have affected net income by approximately \$189,103 [December 31, 2023 – \$168,258]; in the UK GBP to US dollar foreign exchange rate, with all else being equal, would have affected net income by approximately \$19,706 [December 31, 2023 – \$14,670].

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instruments will fluctuate because of changes in market interest rates.

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

13. CAPITAL RISK MANAGEMENT

The Company's objective when managing capital is to safeguard its accumulated capital in order to maintain the ability to continue as a going concern and provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of issues of notes payable, common shares and warrants totaling \$104.3 million as at September 30, 2024

To address this risk, the Company manages its capital structure and makes adjustments to it in light of economic conditions. Upon approval of the Board, the Company balances its overall capital structure through new share or debt issuances, or by undertaking other activities as deemed appropriate in the circumstances.

The Company is not subject to any capital requirements imposed by a lending institution or regulatory body, other than of the Toronto Stock Exchange ("TSX") which requires adequate working capital or financial resources such that, in the opinion of TSX, it will be able to continue as a going concern.

The Company's ability to continue as a going concern depends upon its ability to achieve profitable operations and raise additional capital. From 2019 to 2023, the Company completed a series of common share, structured notes payable, capital commitment, common share and warrant and convertible debenture financings.

14. FINANCE AND TRANSACTION COSTS

	Three-month period ended September 30		Nine-month period ended September 30	
	2024	2023	2024	2023
	\$	\$	\$	\$
Interest on note payable to HDL	34,180	20,757	100,380	90,594
Interest on note payable to shareholder and director	7,137	4,458	16,097	7,500
Interest on convertible debenture	-	-	2,210	7,138
Interest costs on lease liability	5,838	1,639	18,543	11,890
Other interest costs	-	-	3,343	149,453
Total	47,155	26,854	140,573	266,575

15. REVENUE

Revenue and deferred revenue:

	Three-month period ended September 30		Nine-month period ended September 30	
	2024	2023	2024	2023
	\$	\$	\$	\$
Revenue	499,663	745,488	1,411,667	2,205,769
Deferred Revenue	37,685	6,189	37,685	6,189

STAGEZERO LIFE SCIENCES LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE NINE-MONTH PERIOD ENDED September 30, 2024 AND 2023
[EXPRESSED IN US DOLLARS]

16. COMMITMENTS AND CONTINGENCIES

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business